The 19 most recent market catalysts affecting $DFTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78
Canaccord Genuity analyst Sumant Kulkarni maintained a 'Buy' rating on Definium Therapeutics (DFTX) and raised the price target from $64 to $78. This action signals increased analy…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79
Baird analyst Christopher Chen maintained an 'Outperform' rating on Definium Therapeutics (DFTX) and raised the price target from $75 to $79. This action signals continued confiden…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 55
Needham Reiterates Buy on Definium Therapeutics, Maintains $66 Price Target
This 8-K filing discloses that Needham analyst Ami Fadia has reiterated a 'Buy' rating and maintained a $66 price target on Definium Therapeutics (DFTX). This action signals contin…
Sep 11, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Reiterates Outperform on Definium Therapeutics, Maintains $66 Price Target
RBC Capital analyst Brian Abrahams has reaffirmed his 'Outperform' rating and $66 price target for Definium Therapeutics (DFTX). This action signals continued confidence from a maj…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 65
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
The filing details new analyst initiations for five companies by various firms. This is a corporate catalyst as new analyst coverage, especially with 'Buy' or 'Speculative Buy' rat…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 65
B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75
BofA Securities initiating coverage on Definium Therapeutics with a 'Buy' rating and a $75 price target is a significant event for the company. This signals that a major investment…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 65
Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55
Maxim Group, a prominent financial services firm, has maintained its 'Buy' rating on Definium Therapeutics (DFTX) and raised its price target from $50 to $55. This action signals i…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90
Jones Trading analyst Justin Walsh has maintained a 'Buy' rating on Definium Therapeutics (DFTX) and raised the price target from $74 to $90. This upgrade signals increased confide…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64
Canaccord Genuity analyst Sumant Kulkarni has maintained a 'Buy' rating on Definium Therapeutics (DFTX) and raised the price target from $58 to $64. This action signals an analyst'…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Definium Therapeutics (DFTX) and raised the price target from $57 to $66. This action signals a strong v…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Definium Therapeutics, Raises Price Target to $72
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on Definium Therapeutics (DFTX) and raised the price target from $68 to $72. This action signals continued bu…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75
Baird analyst Christopher Chen maintained an 'Outperform' rating on Definium Therapeutics (DFTX) and raised the price target from $57 to $75. This action signals increased confiden…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Definium Therapeutics, Raises Price Target to $66
Needham analyst Ami Fadia maintained a 'Buy' rating on Definium Therapeutics (DFTX) and raised the price target from $50 to $66. This analyst upgrade indicates a more optimistic ou…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 95
Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'
Definium Therapeutics (DFTX) has reported exceptionally strong Phase 3 results for its DT120 ODT in treating generalized anxiety disorder (GAD). The drug met its primary endpoint w…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $75
Piper Sandler analyst David Amsellem has reiterated an 'Overweight' rating on Definium Therapeutics (DFTX) and raised the price target from $73 to $75. This action signals continue…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 65
Wells Fargo Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $68
Wells Fargo's initiation of coverage on Definium Therapeutics (DFTX) with an 'Overweight' rating and a $68 price target is a positive development for the company. Analyst coverage …
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $73
Piper Sandler analyst David Amsellem reiterated an 'Overweight' rating on Definium Therapeutics (DFTX) and raised the price target from $48 to $73. This action indicates a strong v…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
Definium Therapeutics Study Shows High Discontinuation In GAD, Spotlighting Need For Improved Efficacy And Tolerability
Definium Therapeutics (DFTX) released findings from a healthcare claims study demonstrating high rates of treatment discontinuation and switching among both newly diagnosed and est…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.